801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsLyophilized Powder Injection

Oxaliplatin for Injection Lyophilized Powder Injection Anti Cancer Drugs

Oxaliplatin for Injection Lyophilized Powder Injection Anti Cancer Drugs

    • Oxaliplatin for Injection Lyophilized Powder Injection Anti Cancer Drugs
  • Oxaliplatin for Injection Lyophilized Powder Injection Anti Cancer Drugs

    Product Details:

    Place of Origin: China
    Brand Name: Newlystar
    Certification: GMP
    Model Number: Lyophilized, 50mg, 100mg

    Payment & Shipping Terms:

    Minimum Order Quantity: 50000 vials
    Price: Negotiation
    Packaging Details: 10 vials/box
    Delivery Time: 45days
    Payment Terms: L/C, T/T
    Supply Ability: 200, 000 vials per day
    Contact Now
    Detailed Product Description
    Product: Oxaliplatin For Injection Specification: Lyophilized, 50mg, 100mg
    Standard: BP, USP Packing: 10 Vials/box
    High Light:

    lyophilized injection

    ,

    anti cancer drugs

    Oxaliplatin for Injection Lyophilized Powder Injection Anti Cancer Drugs

     

     

    Product : Oxaliplatin for Injection

    Specification : Lyophilized, 50mg, 100mg

    Standard : BP, USP

    Packing : 10 vials/box

     

    Description :

    Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility.

     

    Indication :

    Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.

     

    Pharmacodynamics :

    Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

     

    Mechanism of action

    Oxaliplatin undergoes nonenzymatic conversion to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and transcription. Cytotoxicity is cell-cycle nonspecific.

     

    Usual Adult Dosages :

    To provide adjuvant treatment of stage III colon cancer

    To treat advanced colorectal cancer

    85 mg/m2 I.V. over 2 hr every 2 wk for 12 cycles with 5-fluorouracil 85 mg/m2 I.V. over 2 hr every 2 wk with fluorouracil until disease progression or unacceptable toxicity

    Contact Details
    Newlystar (Ningbo) Medtech Co.,Ltd.

    Contact Person: Luke Liu

    Send your inquiry directly to us (0 / 3000)

    Other Products